Skip to main content
Clinical Trials/ISRCTN16091879
ISRCTN16091879
Completed
未知

A multi-centre clinical study to evaluate the use of a microtrace dose of 14C-labelled midazolam and accelerator mass spectrometry (AMS) bioanalysis as new tools in drug development to determine pharmacokinetics in neonates, infants and toddlers

iverpool Women's NHS Foundation Trust (UK)0 sites25 target enrollmentJune 23, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Medicines for Children
Sponsor
iverpool Women's NHS Foundation Trust (UK)
Enrollment
25
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 23, 2014
End Date
TBD
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
iverpool Women's NHS Foundation Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Infants and toddlers from preterm neonates (32\-36 GW at birth) up to 2 years
  • 2\. Having intravenous or intra\-arterial access suitable for blood sampling
  • 3\. Written informed consent prior to any study\-specific procedures
  • 4\. For dried blood spot sampling in addition to plasma, the participant must weigh more than 2\.3 kg

Exclusion Criteria

  • 1\. History of allergy or hypersensitivity to midazolam
  • 2\. Serious hepatic and/or renal impairment defined as creatinine \> 150 micromol or AST or ALT \> 200
  • 3\. Be otherwise unsuitable for the study, in the opinion of the investigator
  • 4\. Extracorporeal membrane oxygenation (ECMO)
  • 5\. Haemofiltration, peritoneal dialysis, haemodialysis

Outcomes

Primary Outcomes

Not specified

Similar Trials